Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Citation
Voorham , J , Roche , N , Benhaddi , H , van der Tol , M , Carter , V , van Boven , J F M , Bjermer , L , Miravitlles , M & Price , D B 2018 , ' Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK ' , BMJ Open , vol. 8 , no. 10 , e022051 , pp. 1-12 . https://doi.org/10.1136/bmjopen-2018-022051
Rights
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.